Partner With Us NRI

Rossari Biotech Ltd share Price Today

Company details

6M Return 2.16%
1Y Return -6.08%
Mkt Cap.(Cr) 4,527.69
Volume 166,809
Div Yield 0.06%
OI Chg %
Volume 166,809

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Speciality Chemicals company Rossari Biotech announced Q1FY25 results:


  • Revenue from operations grew 19.3% to Rs 489.7 crore as compared to Rs 410.6 crore
  • EBITDA improved by 12.5% to Rs 64.9 crore from Rs 57.7 crore
  • EBITDA margin at 13.3% as against 14.1%
  • PAT increased by 19.5% to Rs 34.9 crore from Rs 29.2 crore
  • EPS (Diluted) stood at Rs 6.3 as against Rs 5.3 


  • Revenue from operations stood at Rs 300.7 crore as against Rs 258.3 crore, up 16.4%
  • EBITDA increased by 13.4% to Rs 39.8 crore as against Rs 35.1 crore
  • EBITDA margin at 13.2% as against 13.6%
  • PAT higher by 12.5% to Rs 24.3 crore as against Rs 21.6 crore
  • EPS (Diluted) stood at Rs 4.4 as against Rs 3.9

Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said “We are pleased to report a strong start to the new financial year, with significant Y-o-Y increases in both revenues and profits by 19.3% and 19.4%, respectively. This performance was largely driven by healthy volume growth both in our HPPC and TSC business. AHN business remained stable during the quarter.

The HPPC and TSC divisions achieved a robust growth of 21%, reflecting the dedicated efforts of our team in a challenging operating environment. We continue to expand our customer base which is significantly contributing to our growth story. By targeting customers in both new and existing geographies, we have delivered a strong performance in the international markets during the current quarter. Going forward, we expect exports to be a key growth vertical, further strengthening our position in the global market.

R&D is a cornerstone of our growth and innovation strategy, strengthening Rossari's position as a leading solutions provider in the specialty chemicals sector. Our robust R&D capabilities enable us to meet evolving market needs and offer bespoke solutions, driving growth, creating value, and enhancing our reputation for intelligent and sustainable solutions. While commodity chemicals have benefited from global industry trends in the last few years, we see a promising shift where solution providers and formulators with strong R&D capabilities like Rossari will lead the way in creating sustainable value for all stakeholders going forward.

Despite the macroeconomic challenges, we remain optimistic about the remainder of the year. Our growth strategy continues to focus on broadening our customer base, expanding our geographies and prioritizing higher margin products. Our commitment to R&D, particularly in developing new and innovative products, positions us favourably for delivering healthy operational and financial performance going forward.”

Result PDF

View Other Company Results

Rossari Biotech Ltd shares SWOT Analysis

Strengths (9)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Effectively using its capital to generate profit - RoCE improving in last 2 years
  • Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Weakness (2)

  • MFs decreased their shareholding last quarter
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (1)

  • RSI indicating price strength

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 834.7
R2 849.8
R3 869.6


S1 799.7
S2 779.9
S3 764.8
Delivery and volume
GOLDMAN SACHS INDIA FUND LIMITED Block Sell 2021-09-20 1478.65 666135 BSE
PUBLIC SECTOR PENSION INVESTMENT BOARD Block Purchase 2021-07-19 1249.5 166875 NSE
Name Category Shares
Edward Menezes PROMOTER 29.18%
Sunil Srinivasan Chari PROMOTER 29.12%
Anita Menezes PROMOTER 1.81%
Jyotishna Sunil Chari PROMOTER 1.81%
Rossari Biotech (India) Private Limited PROMOTER 5.46%


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Rossari Biotech Ltd Stocks COMPARISON

Financials( in Cr) Rossari Biotech Ltd Pidilite Industries Ltd SRF Ltd Linde India Ltd Deepak Nitrite Ltd
Price 819.55 3,150.35 2,367.55 8,104.00 2,851.20
% Change 0.48 -0.36 -1.35 -6.64 4.64
Mcap Cr 4,527.69 160,229.64 70,180.10 69,114.15 38,888.37
Revenue TTM Cr 1,655.88 12,382.99 13,138.52 2,768.67 7,681.83
Net Profit TTM Cr 107.26 1,747.42 1,335.71 434.09 810.89
PE TTM 33.18 89.84 52.70 160.84 53.43
1 Year Return -6.08 21.36 8.22 88.18 43.50
ROCE 17.51 29.30 12.52 17.04 21.56
ROE 12.47 22.37 12.25 13.14 16.38

Equity Capital: 915.17 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 8,937.56 45,192.41
LAST 3M 92,628.05 55,620.51
LAST 6M 175,219.32 60,530.78
LAST 12M 306,910.23 88,097.76
Rossari Biotech schedules AGM

Jul 22, 2024 l BSE Announcement

Rossari Biotech Limited - Other General Purpose

Jul 22, 2024 l NSE Announcement

NSE Board Meetings Forthcomming

Jul 20, 2024 l NSE Board Meetings Forthcomming

Date Action Type Ratio
May 24, 2023 Dividend 25
Jul 07, 2022 Dividend 25

Rossari Biotech Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Rossari Biotech is one of India’s leading chemical and textile manufacturers. The company’s products are used in the paper, construction, pharmaceutical, animal health, and nutrition industries. It has operations in India, Vietnam, Bangladesh, and Mauritius. The company, founded in 2003, operates two research and development facilities in India. It is headquartered in Mumbai, India. 

    On 22 January 2023, the market capitalisation of the company was Rs 3,926.82 crore. It reported a total revenue of Rs 240.9 crore at the end of the second quarter of the financial year 2022-2023. The company is listed on the Bombay Stock Exchange with the code 543213 and on the National Stock Exchange under the code ROSSARI.   

    Rossari Biotech has a diversified shareholding pattern, with promoters holding approximately 68.44% of the company. The public has a stake of 8.87% in the company. FIIs hold a stake of 8.61% in the company, while DIIs hold 14.08%. The shareholding pattern of the company has remained largely stable over the past year.

    Edward Menezes is the current chairman of the company. Other directors of the company include Sunil Chari, Aseem Dhru, Goutam Bhattacharya, Meher Castelino, Robin Banerjee, and Sharabh Pachory. The chief financial officer of Rossari Biotech is Ketan Sablok. The company’s auditors are Deloitte Haskins & Sells LLP.  

    On 22 January 2023, Rossari Biotech’s share price was Rs 710.85 on the BSE and Rs 710.35 on the NSE. The company’s 52-week-high was Rs 1,283.15, while the 52-week-low was Rs 648.00. Its three-month return to investors was -24.6%, while its one-year return was -43.3%.

    The company’s trailing twelve-month (TTM) revenue was Rs 1,482.97 crore as of 31 December 2022. At the same time, the company had a net profit of Rs 97.70 crore. The company’s P/E TTM was 39.4. The ROE of the company was 16.1, while the ROCE of the company was 22.7.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

201 A-B 2nd Floor LBS Marg, Akruti Corporate Park Kanjur(W, Mumbai, Maharashtra, 400079

Tel : 91-22-6123 3800
Email : cs:rossarimail.com
Website : http://www.rossari.com

Link Intime India Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543213
Book Closure Date (Month) : May
BSE Group : A
ISIN : INE02A801020

FAQ’s on Rossari Biotech Ltd Shares

You can buy Rossari Biotech Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Rossari Biotech Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jul 22, 2024 03:58 PM the closing price of Rossari Biotech Ltd was Rs.819.55.

The latest PE ratio of Rossari Biotech Ltd as of Jul 22, 2024 03:58 PM is 33.18

The latest PB ratio of Rossari Biotech Ltd as of Jul 22, 2024 03:58 PM is 0.23

The 52-week high of Rossari Biotech Ltd share price is Rs. 896.45 while the 52-week low is Rs. 656.95

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jul 22, 2024 03:58 PM, the market cap of Rossari Biotech Ltd stood at Rs. 4,527.69 Cr.

Download App

Download Our App

Play Store App Store
market app